GGrantIndex
← Search

SLCO2B1 AND SLCO1B3 AS NEW TARGETS FOR ENHANCING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER

$648,750FY2014Department of the ArmyDOD

Dana-Farber Cancer Institute, Inc.

Investigators

View source on USAspending →
SLCO2B1 AND SLCO1B3 AS NEW TARGETS FOR ENHANCING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER · GrantIndex